Lantheus Holdings, Inc. $LNTH Shares Purchased by Vanguard Group Inc.

Vanguard Group Inc. raised its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 1.7% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,952,418 shares of the medical equipment provider’s stock after acquiring an additional 115,338 shares during the period. Vanguard Group Inc. owned 0.10% of Lantheus worth $356,590,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Hantz Financial Services Inc. boosted its position in Lantheus by 412.5% during the 3rd quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 396 shares during the period. Elevation Point Wealth Partners LLC bought a new stake in Lantheus in the second quarter valued at $26,000. First Horizon Corp acquired a new position in shares of Lantheus during the third quarter valued at $26,000. Osterweis Capital Management Inc. bought a new position in shares of Lantheus during the second quarter worth about $36,000. Finally, Pilgrim Partners Asia Pte Ltd acquired a new stake in shares of Lantheus in the 3rd quarter worth about $59,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Price Performance

NASDAQ LNTH opened at $75.43 on Friday. Lantheus Holdings, Inc. has a 12 month low of $47.25 and a 12 month high of $111.29. The firm has a market capitalization of $5.00 billion, a PE ratio of 31.69 and a beta of -0.08. The company’s 50 day simple moving average is $67.97 and its 200 day simple moving average is $60.01. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.67 and a quick ratio of 2.49.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.17 by $0.50. Lantheus had a return on equity of 30.88% and a net margin of 10.99%.The firm had revenue of $406.79 million during the quarter, compared to analyst estimates of $367.03 million. During the same period last year, the company posted $1.59 EPS. The firm’s quarterly revenue was up 4.0% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, equities research analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

LNTH has been the subject of a number of analyst reports. William Blair raised shares of Lantheus from a “market perform” rating to an “outperform” rating in a research note on Thursday. Truist Financial lifted their price target on Lantheus from $80.00 to $82.00 and gave the company a “buy” rating in a report on Thursday, December 18th. Citigroup reissued an “outperform” rating on shares of Lantheus in a report on Tuesday. Mizuho lifted their target price on Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. Finally, Weiss Ratings upgraded Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, January 6th. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $78.83.

Key Stories Impacting Lantheus

Here are the key news stories impacting Lantheus this week:

• Positive Sentiment: Q4 results materially beat consensus: reported EPS $1.67 vs. $1.17 expected and revenue $406.8M vs. $367.0M expected; margins and ROE were strong, signalling healthy profitability and execution. Lantheus Q4 results and call
• Positive Sentiment: Analyst upgrade: William Blair raised LNTH from Market Perform to Outperform, which can support buying interest and institutional demand. William Blair upgrade
• Positive Sentiment: Price target increase: Citizens Jmp raised its target to $78, which can reinforce the bullish narrative among some investors. Price target raise
• Neutral Sentiment: Earnings call materials and transcripts are available for investors to review management’s commentary and details behind the beat. These provide color but are not new headline news. Earnings call transcript Earnings presentation
• Negative Sentiment: FY‑2026 guidance was modestly conservative: management gave EPS guidance of $5.00–$5.25 (consensus ~$5.16) and revenue guidance roughly $1.4–$1.5B (consensus ~$1.5B). The EPS range is below some analyst expectations (street average cited ~6.01 in background notes), which could cap upside. Company press release with guidance

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.